New-Generation Antibodies Will Allow Aggressive Breast Cancer to Be Diagnosed Easily

In October 2018, Nature Communicationspublished a study in which ultrasmall silica nanoparticles (also known as cornel dots), designed with a HER2 antibody, successfully diagnosed aggressive breast cancer.
Translated into Turkish as bağısan , but almost everyone prefers to use the term antibody ; this term refers to molecules produced by our immune systemagainst structures it recognizes as foreign, molecules with a glycoprotein structure. Antibodies in the body are produced by B cells , although today many antibodies can be produced in the laboratory as medicines. This makes it possible to target molecules associated with diseases (such as receptors). HER2 is an important cell membrane receptor in breast, esophageal, stomach and lung cancer.
Antibodies are important molecules offering major benefits in cancer diagnosis and treatment. Studies aimed at diagnosing cancer using antibodies have increased recently. However, one of the greatest problems in clinical studies is concern about reliability.
Inability to target a tumor effectively is one of the challenges in cancer diagnosis. Oncological imaging involves radioactive material that accumulates in the bone marrow, liver and kidneys. For this reason, attention has focused on nanoparticles designed together with immunological agents.
However, these nanoparticles (larger than 20 nanometers) cannot be excreted by the kidneys. In this study, ultrasmall nanoparticles containing antibodies against HER2 (smaller than 8 nanometers) were designed. In studies using animal models and human cancer cell models, HER2-positive breast cancer cells were successfully targeted with the new-generation nanoparticles.
What Does This Study Tell Us?
- This is the first study to show that antibodies and ultrasmall nanoparticles can be used in cancer diagnosis.
- Ultrasmall nanoparticles designed with a HER2 antibody both effectively target the tumor and can be easily excreted through the kidneys.
- This system that has been designed may facilitate diagnosis of HER2-positive breast cancer.
- It must be emphasized that these nanoparticles are still being tested at the laboratory stage. They will be available for use after their reliability is demonstrated in clinical studies.
Sources
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer.
Nature Communications, September 2018
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.